-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380

Benzinga·11/02/2026 20:08:05
Diffusion vocale
Barclays analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $450 to $380.